克拉黴素
參考文獻

↑   (PDF). List of nationally authorised medicinal products. European Medicines Agency. 2020-12-10.
↑  周本宏,蔡鸿生.大环内酯抗生素新药—甲红霉素[J].中国医院药学杂志, 1994, 014(012):571-572.
1 2 3 4 5 6 7 8 9 10 11 12 13 14  . The American Society of Health-System Pharmacists.   [2015-09-04]. （原始内容存档于2015-09-03）.
↑   Mommersteeg MC, Nieuwenburg SA, Wolters LM, Roovers BH, van Vuuren HA, Verhaar AP, Bruno MJ, Kuipers EJ, Peppelenbosch MP, Spaander MC, Fuhler GM. . United European Gastroenterol J. November 2023, 11 (9): e894–903. PMC 10637120 . PMID 37854002. doi:10.1002/ueg2.12473 .
1 2  Greenwood D.  1. Oxford: Oxford University Press. 2008: 239. ISBN 978-0-19-953484-5. （原始内容存档于2016-03-05）.
↑  Fischer J, Ganellin CR. . John Wiley & Sons. 2006: 498  [2025-01-06]. ISBN 978-3-527-60749-5. （原始内容存档于2024-09-29）.
↑  World Health Organization. . Geneva: World Health Organization. 2019. hdl:10665/325771 . WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
↑  Kirst HA.  2. Basel: Birkhäuser Basel. 2012: 53. ISBN 978-3-0348-8105-0. （原始内容存档于2016-03-05）.
↑  . PunChen.   [2024-12-19]. （原始内容存档于2025-02-06）.
1 2 3 4 5 6 7 8 9 10 11   (PDF). 2015-11-02  [2015-11-02]. （原始内容存档 (PDF)于2015-08-24）.
↑  Trotti LM, Becker LA, Friederich Murray C, Hoque R. . The Cochrane Database of Systematic Reviews. May 2021, 2021 (5): CD012714. PMC 8144933 . PMID 34031871. doi:10.1002/14651858.CD012714.pub2. There is insufficient evidence to conclude whether clarithromycin is effective for the treatment of idiopathic hypersomnia.
↑  Maski K, Trotti LM, Kotagal S, Robert Auger R, Rowley JA, Hashmi SD, Watson NF. . Journal of Clinical Sleep Medicine. September 2021, 17 (9): 1881–1893. PMC 8636351 . PMID 34743789. doi:10.5664/jcsm.9328. Recommendation 9: We suggest that clinicians use clarithromycin (vs no treatment) for the treatment of idiopathic hypersomnia in adults. (CONDITIONAL)
↑   (PDF). American Academy of Sleep Medicine. 2021  [2024-02-25]. （原始内容存档 (PDF)于2024-02-25）.
↑  . Mayo Clinic.   [2024-12-19]. （原始内容存档于2025-01-15）.
↑  . Drugs.com.   [2017-08-18]. （原始内容存档于2017-08-19）.
↑  . U.S. Food and Drug Administration (FDA).   [2018-02-24]. （原始内容存档于2018-04-24）.
↑  Yamaguchi S, Kaneko Y, Yamagishi T, et al. [Clarithromycin-induced torsades de pointes]. Nippon Naika Gakkai Zasshi. 2003;92(1):143–5.
↑  Winkel P, Hilden J, Fischer Hansen J, Hildebrandt P, Kastrup J, Kolmos HJ, Kjøller E, Jespersen CM, Gluud C, Jensen GB. . Cardiology. 2011, 118 (1): 63–7. PMID 21447948. S2CID 11873791. doi:10.1159/000324533.
↑  Tietz A, Heim MH, Eriksson U, Marsch S, Terracciano L, Krähenbühl S. . The Annals of Pharmacotherapy. January 2003, 37 (1): 57–60. PMID 12503933. doi:10.1345/1542-6270(2003)037<0057:flfawc>2.0.co;2.
↑  . eDrug.   [2024-12-20]. （原始内容存档于2025-01-23）.
↑  Hougaard Christensen MM, Bruun Haastrup M, Øhlenschlaeger T, Esbech P, Arnspang Pedersen S, Bach Dunvald AC, Bjerregaard Stage T, Pilsgaard Henriksen D, Thestrup Pedersen AJ. . Basic Clin Pharmacol Toxicol. April 2020, 126 (4): 307–317. PMID 31628882. doi:10.1111/bcpt.13343.
↑  Herdegen T, Cascorbi I. . Dtsch Arztebl Int. December 2023, 120 (49): 833–840. PMC 10824494 . PMID 37874128. S2CID 264438050. doi:10.3238/arztebl.m2023.0223.
↑  Patel AM, Shariff S, Bailey DG, Juurlink DN, Gandhi S, Mamdani M, Gomes T, Fleet J, Hwang YJ, Garg AX. . Annals of Internal Medicine. June 2013, 158 (12): 869–76. PMID 23778904. S2CID 21222679. doi:10.7326/0003-4819-158-12-201306180-00004.
↑  Gandhi S, Fleet JL, Bailey DG, McArthur E, Wald R, Rehman F, Garg AX. . JAMA. December 2013, 310 (23): 2544–53. PMID 24346990. doi:10.1001/jama.2013.282426.
↑  Gélisse P, Hillaire-Buys D, Halaili E, Jean-Pastor MJ, Vespignan H, Coubes P, Crespel A. . Revue Neurologique. November 2007, 163 (11): 1096–9. PMID 18033049. doi:10.1016/s0035-3787(07)74183-8.
↑  Sekar VJ, Spinosa-Guzman S, De Paepe E, De Pauw M, Vangeneugden T, Lefebvre E, Hoetelmans RM. . Journal of Clinical Pharmacology. January 2008, 48 (1): 60–5. PMID 18094220. S2CID 38368595. doi:10.1177/0091270007309706.
↑  Polis MA, Piscitelli SC, Vogel S, Witebsky FG, Conville PS, Petty B, Kovacs JA, Davey RT, Walker RE, Falloon J, Metcalf JA, Craft C, Lane HC, Masur H. . Antimicrobial Agents and Chemotherapy. August 1997, 41 (8): 1709–14. PMC 163990 . PMID 9257746. doi:10.1128/AAC.41.8.1709.
↑  Champney, W S; Tober, C L. . ntimicrobial Agents Chemotherapy. June, 1999, 43 (6): 1324–8  [2024-12-20]. doi:10.1128/AAC.43.6.1324. （原始内容存档于2025-01-23）.  请检查|date=中的日期值 (帮助)
1 2 3 4  Takahashi T, Noriaki S, Matsumura M, Li C, Takahashi K, Nishino S. . Expert Opinion on Orphan Drugs. 3 October 2018, 6 (10): 597–610. ISSN 2167-8707. doi:10.1080/21678707.2018.1521267.
↑  Ferrero JL, Bopp BA, Marsh KC, Quigley SC, Johnson MJ, Anderson DJ, Lamm JE, Tolman KG, Sanders SW, Cavanaugh JH. . Drug Metabolism and Disposition. 1990, 18 (4): 441–6. PMID 1976065.
↑  Vieweg WV, Hancox JC, Hasnain M, Koneru JN, Gysel M, Baranchuk A. . Therapeutic Advances in Infectious Disease. August 2013, 1 (4): 121–138. PMC 4040724 . PMID 25165548. doi:10.1177/2049936113497203.